Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

被引：0
|
作者：
Mohyuddin, Ghulam Rehman [1 ]
Chakraborty, Rajshekhar [2 ]
Calip, Gregory S. [3 ]
Ascha, Mustafa S. [3 ]
Wang, Xiaoliang [3 ]
Rubinstein, Samuel M. [4 ]
Tuchman, Sascha [4 ]
Costa, Luciano [5 ]
Haaland, Benjamin [6 ]
Giri, Smith [5 ]
Mian, Hira [7 ]
Fonseca, Rafael [8 ]
Sborov, Douglas [1 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA
[2] Columbia Univ, Dept Hematol, New York, NY USA
[3] Flatiron Hlth, New York, NY USA
[4] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Dept Med, Div Hematol, Chapel Hill, NC USA
[5] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
[6] Univ Utah, Dept Populat Sci, Salt Lake City, UT USA
[7] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[8] Mayo Clin Arizona, Div Hematol & Oncol, Phoenix, AZ USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 12期
关键词：
D O I：
10.1038/s41408-022-00769-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] HEPATITIS B VIRUS REACTIVATION IN PATIENTS RECEIVING ANTI-CD38 MONOCLONAL ANTIBODIES
    Chiu, Chia-Yu
    Patel, Krina
    Thomas, Sheeba K.
    Khawaja, Fareed
    Garnes, Natalie J. M. Dailey
    Lee, Hans C.
    Ohanian, Maro
    Jiang, Ying
    Wang, Lan S.
    Hwang, Jessica P.
    Torres, Harrys A.
    HEPATOLOGY, 2022, 76 : S236 - S237
  • [42] Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy
    Venglar, Ondrej
    Kapustova, Veronika
    Anilkumar Sithara, Anjana
    Zihala, David
    Muronova, Ludmila
    Sevcikova, Tereza
    Vrana, Jan
    Vdovin, Alexander
    Radocha, Jakub
    Krhovska, Petra
    Hrdinka, Matous
    Turjap, Michal
    Popkova, Tereza
    Chyra, Zuzana
    Broskevicova, Lucie
    Simicek, Michal
    Koristek, Zdenek
    Hajek, Roman
    Jelinek, Tomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1439 - 1449
  • [43] Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapies
    Kikuchi, Taku
    Oda, Yuki
    Kondo, Ukyo
    Tsukada, Nobuhiro
    Kunisada, Kodai
    Matsumoto, Chiaki
    Nomura-Yogo, Moe
    Sato, Kota
    Takei, Tomomi
    Ogura, Mizuki
    Abe, Yu
    Suzuki, Kenshi
    Hosoya, Osamu
    Ishida, Tadao
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (05)
  • [44] CLINICAL CHARACTERISTICS AND EVOLUTION OF PATIENTS WITH MULTIPLE MYELOMA RESISTANT TO ANTI-CD38 TREATMENT
    Herreros Irene, Zamanillo
    Paula Rosalia, De la Puerta
    Manso Rodrigo, Gil
    Garcia Rodrigo, Iniguez
    Santaella Maria, Poza
    Guerrero Elena, Vera
    Soto Marta, Hidalgo
    Maria de las Nieves, Lopez Munoz
    Gil Rafael, Colmenares
    Alos Daniel, Gil
    Fernandez Rafael, Alonso
    Teresa, Cedena Romero
    Robles Maria, Calbacho
    Diaz Rosa, Ayala
    Joaquin, Martinez-Lopez
    HAEMATOLOGICA, 2021, 106 (10) : 143 - 144
  • [45] Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
    Djebbari, Faouzi
    Poynton, Matt
    Sangha, Gina
    Anderson, Laura
    Maddams, Rebecca
    Eyre, Toby A.
    Vallance, Grant
    Basu, Supratik
    Ramasamy, Karthik
    HEMATOLOGY, 2022, 27 (01) : 204 - 207
  • [46] Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
    Kastritis, Efstathios
    Theodorakakou, Foteini
    Stathopoulos, Ioannis-Ntanasis
    Spiliopoulou, Vassiliki
    Solia, Eirini
    Malandrakis, Panagiotis
    Syrigou, Rodanthi
    Kokkali, Nikoleta
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Fotiou, Despina
    Roussou, Maria
    Kanellias, Nikolaos
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    HEMASPHERE, 2023, 7 (11):
  • [47] Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma
    Kastritis, Efstathios
    Fotiou, Despina
    Theodorakakou, Foteini
    Solia, Irene
    Spiliopoulou, Vasiliki
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Kanellias, Nikolaos
    Roussou, Maria
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Dimopoulos, Meletios
    BLOOD, 2024, 144 : 7021 - 7022
  • [48] Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
    Alici, Evren
    Chrobok, Michael
    Lund, Johan
    Ahmadi, Tahamtan
    Khan, Imran
    Duru, Adil D.
    Nahi, Hareth
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (03) : 473 - 477
  • [49] Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
    Zannetti, Beatrice Anna
    Faini, Angelo Corso
    Massari, Evita
    Geuna, Massimo
    Maffini, Enrico
    Poletti, Giovanni
    Cerchione, Claudio
    Martinelli, Giovanni
    Malavasi, Fabio
    Lanza, Francesco
    CELLS, 2020, 9 (12) : 1 - 13
  • [50] Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naive Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics
    Snyder, Jordan
    Mansour, Razan
    Mammadzadeh, Aytaj
    Hashmi, Hamza
    Afrough, Aimaz
    Alkharabsheh, Omar
    Paul, Barry
    Atrash, Shebli
    Mushtaq, Muhammad Umair
    Skikne, Barry S.
    Ahmed, Nausheen
    Abdallah, Al-Ola
    BLOOD, 2023, 142
12345